PAP
ARQT icon

Persistent Asset Partners’s Arcutis Biotherapeutics ARQT Stock Holding History

Persistent Asset Partners’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$227K Buy
+8,657
New +$202K 0.07% 199
2025
Q1 		– Sell
-22,810
Closed -$302K – 176
2024
Q4 		$302K Buy
+22,810
New +$250K 0.25% 82

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Persistent Asset Partners's ARQT Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 8,657 shares worth $227K. The stake represents 0.07% of the portfolio and ranks #199 among its holdings. This is a return to the name: Persistent Asset Partners previously reported a position in ARQT as recently as Q4 2024.

Persistent Asset Partners first reported a position in ARQT in Q4 2024 and has held it in 2 quarters since. The position peaked at $302K in Q4 2024. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Persistent Asset Partners held 8,657 shares of Arcutis Biotherapeutics worth $227K as of Q2 2026.
  • Arcutis Biotherapeutics was a new Persistent Asset Partners position in Q2 2026.
  • Arcutis Biotherapeutics made up 0.07% of Persistent Asset Partners's portfolio in Q2 2026, its #199 holding.
  • Persistent Asset Partners first reported a position in Arcutis Biotherapeutics in Q4 2024 and has held it in 2 quarters since.
  • Persistent Asset Partners's Arcutis Biotherapeutics position peaked at $302K in Q4 2024.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.